CTG-Repeat Transcription Modulators for Defective mRNA Suppression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for inherited genetic diseases such as myotonic dystrophy type 1 (DM1) and Fuchs' endothelial dystrophy do not address the underlying cause of disease progression, which is attributed to the overproduction and aggregation of mRNA with expanded CTG trinucleotide repeats, leading to RNA toxicity and cellular dysfunction.
Innovation Solution
Development of chimeric heterocyclic polyamide compounds that selectively bind to the CTG trinucleotide repeat sequences in target genes (dmpk or tcf4) to modulate gene expression, reducing the production of defective mRNA and alleviating disease symptoms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If current treatments are used for DM1 and FECD, then symptom relief is achieved, but the underlying cause of disease progression (overproduction of defective mRNA) is not addressed
Solution Approach 1:
The patent extracts and targets the specific harmful element (expanded CTG trinucleotide repeat sequences) from the gene sequence using antisense oligonucleotides. These oligos bind specifically to the pathological repeat sequences in the mRNA, extracting them from the cellular environment to prevent their toxic effects while allowing normal gene function to proceed.
Solution Approach 2:
The patent converts the harmful expanded CTG repeat sequences into a target for therapeutic intervention. By designing antisense oligonucleotides that complement these specific sequences, the harmful mRNA is transformed into a detectable and bindable target, enabling its selective degradation and preventing RNA toxicity that causes disease progression.
2Reliability
If the defective gene expression is increased to compensate for loss of function, then some protein activity is restored, but the overproduction of defective mRNA with expanded CTG repeats increases RNA toxicity
Solution Approach 1:
The patent removes the harmful component (defective mRNA with expanded CTG repeats) from the cellular environment through antisense oligonucleotide binding. This extraction prevents the defective mRNA from accumulating and forming toxic aggregates, while allowing normal transcription to proceed without generating harmful RNA species.
Solution Approach 2:
The patent introduces an intermediary substance (antisense oligonucleotide) that mediates between the defective gene and the cellular machinery. These oligos bind to the expanded CTG sequences in the mRNA, acting as intermediaries that prevent the defective mRNA from interacting with cellular proteins and forming toxic aggregates, while allowing normal gene expression to function.
3Ease of operation
If traditional symptom-based treatments are used, then quality of life is improved, but the disease progression is not stopped or reversed
Solution Approach 1:
The patent performs preliminary action by targeting and degrading the defective mRNA before it can accumulate to toxic levels and cause disease progression. The antisense oligonucleotides are administered to prevent the formation of harmful RNA aggregates, stopping the disease process at its source rather than treating symptoms after they manifest.
Solution Approach 2:
The patent converts the harmful expanded CTG repeat sequences into a specific target for therapeutic intervention. By designing oligonucleotides that complement these sequences, the disease mechanism itself becomes the target for cure, transforming the pathological feature into a beneficial target for stopping disease progression and potentially reversing symptoms.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds effectively reduce the occurrence, severity, or frequency of symptoms associated with DM1 and FECD by modulating the expression of defective target genes, providing a potential cure rather than just symptom relief.
Implementation Method 1
chimeric heterocyclic polyamide compounds that selectively bind to the CTG trinucleotide repeat sequences in target genes (dmpk or tcf4)
Data Source
AI summary
The present disclosure relates to transcription modulator molecule compounds, compositions, and methods of treating DM1 and FECD.